Izervay injections for geographic atrophy led to acute IOP increases in 3% of eyes in a real-world dataset published in ...

Chief Executive Officer Craig Parker used a discussion at a 2026 investor summit to outline the company’s focus on Wnt pathway biology and antibody engineering, with an emphasis on retinal vascular ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...

Ocular Therapeutix said it would release topline data from its Phase 3 superiority clinical trial of its Axpaxli treatment of wet age-related macular degeneration on Tuesday. Detailed data will be ...

The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...

Could preserved vision be part of the growing list of health benefits associated with GLP-1 drug use? New research suggests ...

Throughout February, @HopkinsMedicine experts from the Wilmer Eye Institute are available to discuss prevention and ...

Retinal vein occlusion (RVO) is the second most common retinal vascular disease worldwide, following diabetic retinopathy.

Central vision loss from Age-related Macular Degeneration can begin subtly, faces blur, words distort, yet side vision remains intact. An eye specialist explains why early screening after 50 is ...

Doctors have found that metformin, an everyday medicine for diabetes, is associated with less progression of age-related macular degeneration (AMD), the commonest cause of blindness in western ...

This is also called age-related macular degeneration (AMD), as the major risk factor for this is aging. It is an eye disorder characterized by a number of conditions negatively affecting the macula.